Glenmark Pharma gets DCGI nod for clinical trials of Favipiravir tablets on COVID-19 patients

Having internally developed the active pharmaceutical ingredients (API) and the formulations for the product, the company filed the product for clinical trials with the DCGI and has received approval for conducting the trial on mild to moderate patients, Glenmark Pharmaceuticals said in a statement.

from Moneycontrol Business News https://ift.tt/2zJWe9B